Day One

Wednesday September 24th 2014

 

8.00 Breakfast and Registration 

  

 

..........................................................................................................................................................................................................

8.20 Chair's Welcome Address 

   Janine Schuurman
VP Research
Genmab

..........................................................................................................................................................................................................

8.30 How can the Lessons Learned from DVD-Ig™ Platform Development be Applied to Other Bispecific Molecules 

  • The structural and functional aspects of the DVD-Ig™ format
  • Potential implications of structural aspects of various bi– (dual-) specific formats on functional outcomes
  • Design of “new” bi- and multi-specific antibody-based formats
  
Tariq Ghayur
Senior Research Fellow
Abbvie

..........................................................................................................................................................................................................

9.00 Designing and Discovering Transformative Bispecific Antibody Therapeutics 

  • CrossMab technology to generate bispecific antibodies by IgG domain exchange that retain its IgG-like properties
  • pREDs innovative Brain Shuttle technology increases the delivery of therapeutics across the blood brain barrier
  • Combing common light chain approaches and novel display technologies to discover cooperative pairs of antibodies
   Martin Steegmaier,
Head, Discovery Unit, LMR
Roche

..........................................................................................................................................................................................................

09.30 Speed Networking & Morning Refreshments 

The Speed Networking sessions are the most valuable hour you’ll spend at the conference and a great opportunity to introduce yourself to the attendees that you would like to have more in-depth conversations with. This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the field and establish meaningful business relationships..

..........................................................................................................................................................................................................

Discovery Stream   Development Stream
Uncovering Target Biologies Amenable to Multispecific Therapy 
     Progressing Your Lead Through to Successful
Proof of Concept 

 

11.00 A Novel Bispecific Antibody Targeting EGFR and cMET with Multiple Mechanisms of Action 

  • Rationale for selecting EGFR-cMet pair for bispecific targeting
  • Preclinical data supporting multiple mechanisms of action of JNJ-61186372
  • Preclinical efficacy of JNJ-61186372 in several in vivo models
Sheri Moores, Principal Scientist, Janssen
  

 

11.00 Testing Strategies for the Assessment of Bispecific T Cell-Engaging BiTE® Antibodies 

  • Performing effective assessments of BiTE ® constructs during preclinical development
  • Translating lessons learned into optimized testing strategies

Benno Rattel, Executive Director, Nonclinical Development, Amgen Research (Munich) GmbH

11.30 Complexity of Bispecific Antibodies Targeting Cell Surface Receptors 

  • Safety and efficacy implications in designing bsAbs engaging cell surface receptors 

  • Structural and development properties in selecting the right drug development candidate

Jijie Gu, Principal Scientist, Abbvie

  

11.30 Late Stage Development of a HER-Targeted Bispecific Therapeutic 

  • Engineering and optimization of drug-like properties beyond just efficacy to create more stable constructs
  • Ensuring candidates have good manufacturability attributes, and can be effectively formulated
  • Ways to create scalable and robust manufacturing processes

Neeraj Kohli, Associate Director, Merrimack

..........................................................................................................................................................................................................

12.00 Networking Lunch

..........................................................................................................................................................................................................

1.30 Addressing Challenges to Transporting Antibodies Across the Blood-Brain Barrier 

  • A bispecific antibody platform targeting TfR improves antibody transport across the BBB
  • BBB uptake mediated by TfR is robust and non-exhaustible
  • Recent data demonstrate the safety and efficacy of the TfR bispecific antibody technology in multiple animal models

James Ernst, Senior Scientist, Genentech

  

1.30 An IL-23/IL-17A/F Bispecific Antibody Demonstrates Efficacy and Biophysical Properties Favorable for Development

  • An overview of a multispecific antibody as a potential innovative therapeutic for inflammatory disorders
  • Biophysical and production properties similar to traditional antibodies
  • Efficacy demonstrated in marmoset EAE model


Brenda Stevens, Senior Scientist, BMS

2.00 Novel Therapeutic Concepts with Bispecific DARPins 

  • Identifying novel target biology and what combinations work
  • Case study examples from oncology and non-oncology indications
Daniel Snell, VP, Biology, Molecular Partners
  

2.00 Current Challenges and Opportunities in Toxicity Assessment of Multispecific Biologics 

  • How to determine whether there is an appropriate non-clinical species to test safety liabilities
  • Importance of understanding target expression/distribution and biology for all targets
  • Integration of nonclinical data to enable first in-human dose selection

Rodney Prell, Senior Toxicologist, Genentech

2.30 Panel: Why use a Bispecific in the First Place? 

  • Is it possible to identify target criteria for different format types?

  • Challenge of finding novel target pairs

  • Defining optimal antigen expression patterns

Selected conference speakers and attendees

 

2.30 Panel: How can we Improve the Predictability of Preclinical Research in Preparation for In-Human Testing 

  • Developing reliable disease models
  • Effective assays to test proof-of-concept studies
  • What else do we need?

Selected conference speakers and attendees

3.00 Afternoon Refreshments

..........................................................................................................................................................................................................

3.30 Chair’s Stream Summaries 

   Janine Schuurman
VP Research
Genmab

..........................................................................................................................................................................................................

Creating Superior Bispecific Compounds

..........................................................................................................................................................................................................

3.45 Development of B Lymphocyte Targeted Bispecific DART Molecules for the Treatment of Autoimmune Disorders

  • MGD010 is a half-life extended bispecific DART protein that coligates the inhibitory Fcγ receptor IIb (CD32B) and the B cell receptor component, CD79B, on B cells
  • CD32B x CD79B DARTs engage CD32B in a BCR-dependent manner and inhibit B cell activation without B cell depletion
  • In vitro and in vivo safety, PK and efficacy studies that support the initiation of clinical development of MGD010 will be presented
  
Syd Johnson,
VP, Antibody Engineering, Macrogenics

..........................................................................................................................................................................................................

4.15 Strategies and Challenges in Analytical Testing of Nano body-Based Multispecifics 

  • Implications for the development of analytical methods
  • Focus on methods to assess product quality and stability for in-process and release samples
  • Analytical challenges for product characterization
   Ann Brige,
Team Leader, CMC Analytic, Ablynx

..........................................................................................................................................................................................................

4.45 Generation of Dual-Targeting Antibodies and their Pre-clinical Development

  • Bispecific designs based on "knob" and "hole" heterodimerization sites in the CH3 domains of two antibody heavy chains
  • Using X-ray crystallography to better understand the knob-into-hole interface, the molecular mechanism of heterodimerization, and to engineer Fc domains that could improve the assembly and purity of the construct
  

Justin Scheer
Senior Scientist
Genentech

..........................................................................................................................................................................................................

5.15 Drinks Reception & Networking 

..........................................................................................................................................................................................................